State Street SPDR S&P Biotech ETF XBI
155.26 USD +3.21 (+2.11%)
Nov 3, 2026, 3:24 PM EST
152.83 Day range 156.92
106.30 52-week range 169.89
- YTD
- +27.34%
- 1 year
- +41.33%
News
247wallst.com Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge Tempus AI (NASDAQ:TEM | TEM Price Prediction) was trading higher this afternoon. It sat at $80.31, up 11.21% after the precision medicine company reported third-quarter results before the open.
247wallst.com Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs Regeneron (NASDAQ:REGN | REGN Price Prediction) shares rose 13.55% in Friday's session, trading at $929.69 as of 9:45 AM ET on Oct 30, 2026. For a biotech worth roughly $94.
zacks.com ETFs That You May Consider Amid a Strengthening Biotech Outlook Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.
zacks.com Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)? If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the State Street SPDR S&P Biotech ETF (XBI), a passively managed exchange traded…
fool.com Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? Both of these ETFs look the part, but only one is truly the better buy for investors.
247wallst.com Why $55 Million Flowed Into a Triple-Leveraged Biotech ETF Worth Less Than $600 Million Traders poured tens of millions into a triple-leveraged biotech fund in a single day, a move that looks like bold conviction until you see what that same bet returned over five years.
defenseworld.net SPDR S&P Biotech ETF $XBI Stock Sold by Banque Pictet & Cie SA Banque Pictet and Cie SA lowered its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 68.8% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 16,770…
defenseworld.net Traders Purchase Large Volume of Call Options on SPDR S&P Biotech ETF (NYSEARCA:XBI) SPDR S&P Biotech ETF (NYSEARCA:XBI - Get Free Report) saw unusually large options trading activity on Thursday. Stock investors acquired 57,758 call options on the stock. This is an increase of…
etftrends.com From Laggard to Leader: The Surprising Comeback of Healthcare Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's…
etftrends.com Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big…
defenseworld.net SPDR S&P Biotech ETF $XBI Stock Acquired by Ayalon Insurance Comp Ltd. Ayalon Insurance Comp Ltd. grew its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 71.9% in the third quarter, according to the company in its most recent 13F filing with the Securities…
fool.com Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech The Fidelity MSCI Health Care Index ETF offers a significantly lower expense ratio and a more diversified portfolio than the State Street SPDR S&P Biotech ETF. The State Street SPDR S&P Biotech ETF…
fool.com Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals The State Street SPDR S&P Biotech ETF and State Street SPDR S&P Pharmaceuticals ETF carry identical 0.35% expense ratios. The State Street SPDR S&P Pharmaceuticals ETF has historically exhibited…
benzinga.com Nasdaq 100 Climbs as Cooler PCE Cuts Rate Hike Bets, Micron Earnings Loom: Stock Market Today Nasdaq 100 gains as softer PCE inflation cools Fed rate-hike bets, with oil above $91 and Micron earnings due after the bell Wednesday.
zacks.com Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? Making its debut on 01/31/2006, smart beta exchange traded fund State Street SPDR S&P Biotech ETF (XBI) provides investors broad exposure to the Health Care ETFs category of the market.
benzinga.com Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
benzinga.com Economy Grows 63% in Six Years, 30-Year Treasury Lost Almost As Much Over six years, U.S. nominal GDP rose 63% while the 30-year Treasury fell 60%. Are investors positioned for a surge in stocks and yields?
fool.com VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors? VHT offers significantly lower ownership costs, with a 0.09% expense ratio compared to XBI's 0.35%. XBI provides targeted focus on biotechnology, while VHT offers exposure to the entire healthcare…
benzinga.com Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
benzinga.com Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation.
seekingalpha.com XBI: Big Pharma Can Keep The 76% Rally Going State Street SPDR S&P Biotech ETF (XBI) is rated Buy, with 8%-14% total return expected over 6-12 months despite a 76% prior-year rally. XBI's modified equal-weight structure offers broad exposure to…
benzinga.com What's Going On With Novavax Stock? Shares of Novavax are trading higher Tuesday. The stock is up over 30% over the trailing month as traders weigh updated autumn vaccine authorizations against the company's broader strategic pivot…
benzinga.com Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive…
benzinga.com Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
zacks.com Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
benzinga.com Novavax Stock Climbs Monday: What's Going On? Shares of Novavax are trading higher Monday, extending its 30% monthly gains on COVID-19 vaccine approvals and broader biotech strength.
benzinga.com QUICK SPARK: $3.8B SPY Exodus Meets $3.7B QQQ Inflow in One Day QQQ attracted $3.67 billion in ETF inflows while SPY saw $3.82 billion in outflows, as semiconductor ETFs also drew strong investor demand.
fxempire.com XBI Forecast: $174.79 Tests Biotech ETF Breakout Strength XBI approaches its 2021 high at $174.79 after a bullish flag breakout, setting up a key test between further gains and a potential consolidation.
zacks.com Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)? Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the…
benzinga.com Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For MRK, MRNA's cancer vaccine breakthrough could revive the mRNA trade, putting biotech and genomics ETFs back in focus.
benzinga.com Novavax Stock Moves Higher Wednesday: What's Driving the Action? Shares of Novavax Inc (NASDAQ: NVAX) are trading higher Wednesday. The move comes as a major clinical victory in the oncology space generated widespread momentum across vaccine developers.
benzinga.com ‘Never Happened in History,’ Ex-Bridgewater Exec Warns AI Market Is Priced to Perfection Former Bridgewater exec Bob Elliott warns the AI stock rally is an "expectations mania" built on unrealistic growth assumptions.
benzinga.com Here's How Much $100 Invested In State Street SPDR S&P Biotech ETF 20 Years Ago Would Be Worth Today State Street SPDR S&P Biotech ETF (NYSE:XBI) has outperformed the market over the past 20 years by 3.16% on an annualized basis producing an average annual return of 12.55%. Currently, State Street…
benzinga.com Bulls Pile Into Moderna As FDA Decision Nears, Ignites 60% Surge In This ETF Moderna shares have surged nearly 30% in five days, ahead of a key FDA advisory vote on its flu vaccine, lifting the leveraged MRNX ETF more than 60%.
benzinga.com Apogee Stock Slides After Blackstone Financing Deal And Positive Drug Data Apogee shares fell after announcing a $1.3 billion Blackstone financing deal alongside positive Phase 2 eczema drug results.
benzinga.com Taiwan Semiconductor, Freeport-McMoRan And More On CNBC's 'Final Trades' Stephen Weiss chose Taiwan Semiconductor as final trade, citing partnership with Applied Materials. Other picks? Freeport-McMoRan.
benzinga.com Moderna's Legal Hit Steals Spotlight From Strong Sales MRNA revenue hits $389M, beating Wall Street estimates. Despite a Q1 loss, Moderna eyes 10% growth and new flu vaccine approvals in 2026.
benzinga.com Tech Leads, Dow Lags As Oil Holds Near $92: What's Moving Markets Wednesday? U.S. stocks were mixed at midday Wednesday as tech stocks rallied while industrials dragged the Dow lower. Oil held above $90 and yields ticked higher, reflecting lingering geopolitical risk.
benzinga.com Citigroup, Morgan Stanley, CBRE Group And More On CNBC's 'Final Trades' Experts predict higher stock prices for CBRE Group and Morgan Stanley, while State Street SPDR S&P Biotech ETF and Citigroup are recommended.
benzinga.com Neurocrine Buys Soleno To Tap High-Growth Rare Disease Market Neurocrine (NBIX) to acquire Soleno Therapeutics (SLNO) for $2.9B to expand its rare disease portfolio. Get the deal details here.
benzinga.com $1000 Invested In State Street SPDR S&P Biotech ETF 20 Years Ago Would Be Worth This Much Today 
benzinga.com Biotech ETF With A Twist: Defiance To Donate Initial Advisory Profits To Autism Causes Ahead of April, also the autism acceptance month, Defiance filed for a biopharma ETF with a pledge to donate profits to autism services and research.
benzinga.com BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress BridgeBio Pharma shares Phase 3 trial update, but early data show progress for rare muscle disease treatment.
benzinga.com FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars Moderna's mRNA-1010 flu vaccine clears FDA review, with stock rising ahead of major approvals.
benzinga.com PTC Therapeutics Pulls Translarna Bid After FDA Flags Weak Proof PTC Therapeutics, Inc. (PTCT) stock closed lower following the withdrawal of its New Drug Application for Translarna by the FDA.
benzinga.com Moderna, Mexico Partner To Boost Local Vaccine Production Moderna signs a long-term deal with Mexico to build local mRNA production, transfer technology, and supply up to 10 million COVID vaccine doses for the 2025–2026 campaign.
benzinga.com Novavax Stock Is Surging Monday: What's Driving The Action? Novavax shares are up on Monday following a licensing agreement with Pfizer for the use of its Matrix-M adjuvant.
benzinga.com Moderna (MRNA) Stock Pulls Back After Recent Strength Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.
benzinga.com Why Your Pneumonia Shot Is About To Get A Massive Upgrade Vaxcyte shares rise after starting Phase 3 trials for its VAX-31 pneumonia vaccine, expanding studies in adults and infants while planning major U.S. manufacturing investments.
benzinga.com Moderna Stock Explodes To New 52-Week High: What's Driving The Action? Moderna Inc (NASDAQ: MRNA) stock is trading higher Thursday morning, hitting a new 52-week high after new cancer trial data.